IGFBP7 and glioma: Our data suggest that IGFBP7-modified sEVs represent a novel platform that enables highly efficient, glioma VECs-targeted delivery of therapeutics into glioma, and are adaptable to a broad spectrum of agents, especially immunomodulators.